Blar i St. Olavs hospital på forfatter "Garred, Øystein"
-
Assessing treatment response and prognosis by serum and tissue metabolomics in breast cancer patients
Debik, Julia Barbara; Euceda, Leslie R.; Lundgren, Steinar; Gythfeldt, Hedda; Garred, Øystein; Borgen, Elin; Engebråten, Olav; Bathen, Tone Frost; Giskeødegård, Guro F. (Journal article; Peer reviewed, 2019)Patients with locally advanced breast cancer have a worse prognosis compared to patients with localized tumors and require neoadjuvant treatment before surgery. The aim of this study was to characterize the systemic metabolic ... -
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
Røssevold, Andreas Hagen; Andresen, Nikolai Kragøe; Bjerre, Christina Annette; Gilje, Bjørnar; Jakobsen, Erik Hugger; Raj, Sunil Xavier; Falk, Ragnhild Sørum; Russnes, Hege Elisabeth Giercksky; Jahr, Thea; Ruud, Randi Margit; Lømo, Jon; Garred, Øystein; Chauhan, Sudhir Kumar; Lereim, Ragnhild Reehorst; Dunn, Claire; Naume, Bjørn; Kyte, Jon A (Peer reviewed; Journal article, 2022)Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast cancer (mTNBC) but only for PD-L1positive disease. The randomized, placebo-controlled ALICE trial (NCT03164993, 24 May 2017) evaluated ... -
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Gythfeldt, Hedda von der Lippe; Lien, Tonje Gulbrandsen; Tekpli, Xavier; Silwal-Pandit, Laxmi; Borgen, Elin; Garred, Øystein; Skjerven, Helle; Schlichting, Ellen; Lundgren, Steinar; Wist, Erik; Naume, Bjørn; Kristensen, Vessela N.; Børresen-Dale, Anne-Lise; Lingjærde, Ole Christian; Engebråten, Olav (Peer reviewed; Journal article, 2020)Antiangiogenic drugs are potentially a useful supplement to neoadjuvant chemotherapy for a subgroup of patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer, but reliable biomarkers for ...